Innoviva Inc  

(Public, NASDAQ:INVA)   Watch this stock  
Find more results for NASDAQ:THRX
-0.07 (-0.63%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.34 - 11.73
52 week 6.36 - 21.16
Open 11.05
Vol / Avg. 1.62M/725,123.00
Mkt cap 1.30B
P/E     -
Div/yield 0.25/9.07
EPS -0.16
Shares 117.42M
Beta 1.79
Inst. own 84%
May 4, 2016
Q1 2016 Innoviva Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 3, 2016
Q4 2015 Innoviva Inc Earnings Call
Feb 3, 2016
Q4 2015 Innoviva Inc Earnings Release
Nov 18, 2015
Theravance Inc at Stifel Healthcare Conference
Nov 11, 2015
Theravance Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 18.83% -34.77%
Operating margin 75.73% 58.54%
EBITD margin - 58.54%
Return on average assets 4.00% -3.97%
Return on average equity - -
Employees 13 -
CDP Score - -


951 Gateway Blvd
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Innoviva, Inc., formerly Theravance, Inc., is an asset management company that is focused on the development, commercialization and financial management of bio-pharmaceuticals. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI), with the intention of providing capital returns to stockholders. Its RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2 agonist (LABA), and fluticasone furoate (FF), an inhaled corticosteroid (FF/VI) delivered through the ELLIPTA dry powder inhaler. Its ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), which is used for the treatment of chronic obstructive pulmonary diseases (COPD).

Officers and directors

William H. Waltrip Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 60
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 61
Bio & Compensation  - Reuters
Paul Pepe Independent Director
Age: 56
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters